FB
2 × $54.99 
AHK-Cu
2 × $30.00 
Super Blend
2 × $50.00 
Lemon Bottle
2 × $45.00 Subtotal: $359.98
Type Growth Hormone-Releasing Hormone (GHRH) Analog CAS Number 218949-48-5 Molecular Weight 5135.9 g/mol Molecular Weight (Cu) N/A Amino Acids 44 Amino Acids Sequence trans-3-Hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
High-purity synthetic peptideSensitive to temperature fluctuations after reconstitutionStable in lyophilized form Lyophilized (powder) -20°C · up to 2 years Reconstituted 2-8°C · up to 30 days
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) consisting of 44 amino acids with a specialized hexenoyl group attached to the N-terminal. This structural modification enhances its resistance to enzymatic degradation, allowing for sustained somatotroph stimulation. In research settings, Tesamorelin is primarily investigated for its unique ability to reduce visceral adipose tissue (VAT) through the growth hormone-mediated lipolytic pathway. Beyond metabolism, it is also a subject of study in neurobiology for its potential role in improving cognitive performance and managing neurodegenerative markers. This high-purity lyophilized reagent provides a stable framework for exploring the endocrine axis and metabolic homeostasis in experimental models.
The mechanism involves Tesamorelin binding to GHRH receptors in the anterior pituitary gland. This stimulation triggers the pulsatile release of endogenous growth hormone (GH), which subsequently travels to the liver to stimulate IGF-1 production. In adipose tissue, the increased GH levels activate hormone-sensitive lipase, leading to the breakdown of visceral fat (lipolysis). Unlike other secretagogues, Tesamorelin preserves the natural feedback loop, ensuring regulated GH levels during research assays.
Metabolic Research 98 Purity Percentage (HPLC Verified) Visceral Fat Reduction Signaling Tesamorelin Group 15.4% (VAT Reduction) Control Group 1.2% Trial details: Investigative studies examining the long-term impact of GHRH stimulation on body composition and lipolysis in metabolic research models. Endocrine Results
Findings from somatotroph activation studies
92% IGF-1 Elevation Optimized GH Axis Signaling 87% Visceral Lipolysis Reduced Abdominal Fat Deposits Note: esults highlight the compound’s precision in targeting fat metabolism without affecting subcutaneous fat.
Somatotroph Receptor Binding
Research focusing on the binding affinity and stability provided by the N-terminal hexenoyl modification.
Visceral Lipolysis Studies
Investigating the targeted reduction of deep abdominal fat and its impact on metabolic health.
Neuro-Cognitive Signaling
Studies exploring the relationship between GHRH stimulation and hippocampal function in aging models.
Endocrine Homeostasis
Exploration of the peptide’s role in maintaining a physiological growth hormone/IGF-1 balance.
Tesamorelin: A Targeted GHRH Analog for Metabolic Homeostasis
A comprehensive analysis of the peptide’s impact on body composition and the GH axis.
Falutz J. & Mamputu J.H. (2024) View Full Study
How does Tesamorelin differ from other GHRH analogs?
It features a hexenoyl group attached to its N-terminal, which significantly increases its stability and potency compared to natural GHRH.
What is the primary research focus of this peptide?
It is extensively studied for its ability to reduce visceral adipose tissue (VAT) and its impact on cognitive function in aging models.
Frequently bought together: Semax 10MG, BPC & TB Blend, BPC-157
